- Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
For: Neoplasm Malignant · Renal Cell Carcinoma · Hormone Receptor Positive Breast CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
For: Solid TumorsUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
This study looks at new ways to treat advanced bladder cancer using a drug called avelumab, often combined with other medicines. Researchers want to see if these combinations are safe and effective in helping patients whose cancer has spread or is hard to treat.
For: Locally Advanced or Metastatic Urothelial CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
For: Advanced Malignancies · NSCLC · Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
This study is testing new treatments for advanced bladder cancer. It compares a new drug, zelenectide pevedotin, alone and with pembrolizumab, against standard chemotherapy. We want to see how well these treatments work and if they are safe for people with bladder cancer that has spread.
For: Metastatic Urothelial CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.
For: Triple Negative Breast Cancer · Locally Advanced Breast Cancer · Recurrent Breast CancerUnited Kingdom - Active not recruitingPHASE2
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
This study looks at a new drug called avelumab for men with advanced penile cancer. It's for those who can't have standard chemotherapy or for whom it has stopped working. We want to see if avelumab can help shrink their tumours.
For: Penile Cancer · Advanced Cancer · Metastatic CancerCanada - AuthorisedTherapeutic exploratory (Phase II)
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025
This study is looking at a new treatment called avelumab for people with a type of cancer that has spread. It compares avelumab to other common care after initial chemotherapy to see how well it works and if it helps people live longer and feel better.
For: metastatic urothelial carcinomaItaly - RecruitingPHASE2
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
This study compares two chemotherapy plans (3 vs 6 cycles) followed by a drug called avelumab for advanced bladder cancer. Doctors want to see how each plan affects patients' quality of life.
For: Urinary Bladder NeoplasmsFrance · Spain · United Kingdom - Active not recruitingPHASE1
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
This study is looking at two new drugs, Avelumab and Lenvatinib, combined together to treat children and teenagers with specific types of brain tumours. It aims to find the right dose and see how well this combination works.
For: Central Nervous System TumorsCanada · France · Germany - Active not recruitingPHASE2
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
This study looks at combining two cancer drugs, tuvusertib and avelumab, for people with advanced Merkel cell skin cancer that hasn't responded to previous treatment. It aims to see if the combination works better than tuvusertib alone to stop the cancer from getting worse.
For: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 · Locally Advanced Merkel Cell CarcinomaUnited States · Canada - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance